Moshe Sade-Feldman, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myeloid Cells | 8 | 2021 | 822 | 0.990 |
Why?
|
Melanoma | 13 | 2024 | 5694 | 0.890 |
Why?
|
Sequence Analysis, RNA | 5 | 2024 | 2011 | 0.740 |
Why?
|
Neutrophils | 3 | 2023 | 3763 | 0.510 |
Why?
|
Single-Cell Analysis | 5 | 2024 | 2452 | 0.500 |
Why?
|
HLA-DR Antigens | 1 | 2016 | 606 | 0.470 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2024 | 4574 | 0.400 |
Why?
|
Antigen Presentation | 1 | 2017 | 1251 | 0.390 |
Why?
|
Immunotherapy | 7 | 2024 | 4642 | 0.390 |
Why?
|
Sepsis | 2 | 2023 | 2585 | 0.380 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2023 | 5301 | 0.330 |
Why?
|
Tumor Microenvironment | 11 | 2024 | 3875 | 0.290 |
Why?
|
Inflammation | 7 | 2015 | 10759 | 0.230 |
Why?
|
Mice, Inbred C57BL | 8 | 2024 | 22128 | 0.220 |
Why?
|
Chemokine CXCL9 | 1 | 2023 | 135 | 0.220 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2013 | 4340 | 0.200 |
Why?
|
Viremia | 2 | 2022 | 707 | 0.190 |
Why?
|
Osteopontin | 1 | 2023 | 302 | 0.190 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2024 | 4373 | 0.180 |
Why?
|
Sterol Regulatory Element Binding Protein 2 | 1 | 2020 | 56 | 0.180 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9187 | 0.180 |
Why?
|
Cell Polarity | 1 | 2023 | 638 | 0.170 |
Why?
|
Transferrin | 1 | 2020 | 283 | 0.170 |
Why?
|
Cross Reactions | 1 | 2021 | 819 | 0.170 |
Why?
|
Endothelium | 1 | 2022 | 763 | 0.160 |
Why?
|
Cryosurgery | 1 | 2024 | 474 | 0.160 |
Why?
|
Cysteine | 1 | 2024 | 888 | 0.160 |
Why?
|
Immune Evasion | 1 | 2023 | 364 | 0.160 |
Why?
|
Pulmonary Alveoli | 1 | 2022 | 651 | 0.160 |
Why?
|
Immunoglobulin A | 1 | 2022 | 979 | 0.160 |
Why?
|
Lipogenesis | 1 | 2020 | 214 | 0.160 |
Why?
|
Mice, Inbred BALB C | 3 | 2018 | 6200 | 0.160 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1089 | 0.150 |
Why?
|
T Cell Transcription Factor 1 | 1 | 2018 | 72 | 0.150 |
Why?
|
Head and Neck Neoplasms | 2 | 2023 | 2894 | 0.150 |
Why?
|
Melanoma, Experimental | 1 | 2021 | 561 | 0.150 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2022 | 424 | 0.140 |
Why?
|
Immunity, Humoral | 1 | 2021 | 598 | 0.140 |
Why?
|
Substrate Specificity | 1 | 2021 | 1768 | 0.140 |
Why?
|
T-Lymphocytes | 6 | 2020 | 10203 | 0.140 |
Why?
|
Glycolysis | 1 | 2021 | 836 | 0.140 |
Why?
|
beta 2-Microglobulin | 1 | 2017 | 329 | 0.140 |
Why?
|
Receptors, Immunologic | 2 | 2020 | 1408 | 0.140 |
Why?
|
Mice | 13 | 2024 | 81330 | 0.140 |
Why?
|
Immunoglobulin G | 2 | 2022 | 4537 | 0.130 |
Why?
|
Cell Differentiation | 2 | 2014 | 11512 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1791 | 0.130 |
Why?
|
Sorting Nexins | 1 | 2015 | 26 | 0.130 |
Why?
|
Apyrase | 1 | 2018 | 373 | 0.130 |
Why?
|
Alternative Splicing | 1 | 2021 | 1087 | 0.130 |
Why?
|
Mice, Knockout | 5 | 2021 | 14392 | 0.130 |
Why?
|
Loss of Heterozygosity | 1 | 2017 | 662 | 0.120 |
Why?
|
Leukocytes | 1 | 2023 | 2025 | 0.120 |
Why?
|
Hepatitis C, Chronic | 1 | 2023 | 1027 | 0.120 |
Why?
|
Neoplasms | 6 | 2024 | 22142 | 0.120 |
Why?
|
Macrophages | 2 | 2023 | 5755 | 0.120 |
Why?
|
Neoplasm Metastasis | 3 | 2024 | 4909 | 0.120 |
Why?
|
Antigens, Neoplasm | 1 | 2022 | 1985 | 0.110 |
Why?
|
Animals | 15 | 2024 | 168089 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2014 | 286 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 943 | 0.110 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 16954 | 0.110 |
Why?
|
Humans | 35 | 2024 | 761222 | 0.110 |
Why?
|
Dendritic Cells | 1 | 2024 | 2726 | 0.110 |
Why?
|
Phenotype | 5 | 2022 | 16575 | 0.110 |
Why?
|
Neoplastic Stem Cells | 1 | 2021 | 1348 | 0.100 |
Why?
|
Hepatitis C | 1 | 2023 | 1579 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2021 | 2549 | 0.100 |
Why?
|
Calgranulin A | 1 | 2013 | 80 | 0.100 |
Why?
|
Calgranulin B | 1 | 2013 | 86 | 0.100 |
Why?
|
Neoplasms, Experimental | 1 | 2017 | 1225 | 0.100 |
Why?
|
Point Mutation | 1 | 2017 | 1593 | 0.100 |
Why?
|
Base Sequence | 1 | 2023 | 12404 | 0.100 |
Why?
|
Skin Neoplasms | 3 | 2024 | 5809 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2023 | 3634 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2013 | 585 | 0.090 |
Why?
|
Immunocompromised Host | 1 | 2015 | 858 | 0.090 |
Why?
|
Immunoblotting | 1 | 2013 | 1644 | 0.080 |
Why?
|
B-Lymphocytes | 2 | 2020 | 4744 | 0.080 |
Why?
|
Disease Progression | 4 | 2024 | 13511 | 0.080 |
Why?
|
Fluorouracil | 1 | 2014 | 1642 | 0.080 |
Why?
|
Prognosis | 6 | 2023 | 29688 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13386 | 0.080 |
Why?
|
Membrane Glycoproteins | 1 | 2019 | 3696 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 1240 | 0.070 |
Why?
|
Antigens, CD | 1 | 2018 | 4009 | 0.070 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2219 | 0.070 |
Why?
|
Chemokines | 2 | 2024 | 956 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4567 | 0.060 |
Why?
|
Cells, Cultured | 3 | 2020 | 18927 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3163 | 0.060 |
Why?
|
SOXE Transcription Factors | 1 | 2024 | 73 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2019 | 3610 | 0.060 |
Why?
|
Killer Cells, Natural | 1 | 2013 | 2194 | 0.060 |
Why?
|
Chronic Disease | 3 | 2013 | 9319 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 2270 | 0.050 |
Why?
|
Tumor Necrosis Factors | 1 | 2023 | 109 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5666 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2012 | 2307 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2709 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2013 | 5871 | 0.050 |
Why?
|
STAT Transcription Factors | 1 | 2023 | 189 | 0.050 |
Why?
|
Coronavirus OC43, Human | 1 | 2021 | 18 | 0.050 |
Why?
|
Janus Kinases | 1 | 2023 | 249 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11119 | 0.050 |
Why?
|
Spheroids, Cellular | 1 | 2023 | 329 | 0.050 |
Why?
|
Pentose Phosphate Pathway | 1 | 2021 | 126 | 0.040 |
Why?
|
Female | 11 | 2024 | 392552 | 0.040 |
Why?
|
Gene Expression | 1 | 2013 | 7571 | 0.040 |
Why?
|
Dendritic Cells, Follicular | 1 | 2020 | 50 | 0.040 |
Why?
|
Immunoglobulin Class Switching | 1 | 2021 | 289 | 0.040 |
Why?
|
DNA, Complementary | 1 | 2023 | 1989 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 878 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3593 | 0.040 |
Why?
|
Phthalazines | 1 | 2022 | 383 | 0.040 |
Why?
|
Lymphocyte Activation | 2 | 2021 | 5478 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2021 | 739 | 0.040 |
Why?
|
Complementarity Determining Regions | 1 | 2019 | 149 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2012 | 3092 | 0.040 |
Why?
|
Antigen-Presenting Cells | 1 | 2022 | 965 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2023 | 1695 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 8531 | 0.040 |
Why?
|
Glutathione | 1 | 2021 | 581 | 0.040 |
Why?
|
RNA, Neoplasm | 1 | 2021 | 748 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 2015 | 6919 | 0.040 |
Why?
|
Sirtuins | 1 | 2021 | 320 | 0.040 |
Why?
|
Receptors, Fc | 1 | 2021 | 537 | 0.040 |
Why?
|
Oxidation-Reduction | 1 | 2024 | 2227 | 0.040 |
Why?
|
Virus Internalization | 1 | 2021 | 496 | 0.040 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2022 | 619 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 735 | 0.040 |
Why?
|
Ligands | 1 | 2024 | 3264 | 0.030 |
Why?
|
HLA Antigens | 1 | 2022 | 1331 | 0.030 |
Why?
|
Organoids | 1 | 2023 | 744 | 0.030 |
Why?
|
Clone Cells | 1 | 2020 | 1668 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1602 | 0.030 |
Why?
|
Hepacivirus | 1 | 2023 | 1330 | 0.030 |
Why?
|
NF-kappa B | 1 | 2024 | 2475 | 0.030 |
Why?
|
Leishmania donovani | 1 | 2015 | 68 | 0.030 |
Why?
|
DNA Replication | 1 | 2022 | 1415 | 0.030 |
Why?
|
Leishmaniasis, Visceral | 1 | 2015 | 99 | 0.030 |
Why?
|
Mice, Inbred DBA | 1 | 2015 | 623 | 0.030 |
Why?
|
Mice, Nude | 1 | 2021 | 3606 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6312 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2022 | 6125 | 0.030 |
Why?
|
Middle Aged | 5 | 2024 | 220858 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2023 | 3155 | 0.030 |
Why?
|
Male | 7 | 2024 | 360703 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2019 | 9520 | 0.030 |
Why?
|
Immunologic Memory | 1 | 2020 | 1361 | 0.030 |
Why?
|
Antioxidants | 1 | 2021 | 1667 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2014 | 407 | 0.030 |
Why?
|
Hepatitis | 1 | 2014 | 228 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2189 | 0.030 |
Why?
|
Leucovorin | 1 | 2014 | 643 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2024 | 8519 | 0.030 |
Why?
|
DNA Damage | 1 | 2022 | 2443 | 0.020 |
Why?
|
Cancer Vaccines | 1 | 2019 | 1038 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2021 | 4243 | 0.020 |
Why?
|
Piperazines | 1 | 2022 | 2522 | 0.020 |
Why?
|
Granulocytes | 1 | 2013 | 550 | 0.020 |
Why?
|
Proteome | 1 | 2021 | 1856 | 0.020 |
Why?
|
Antibodies | 1 | 2019 | 2415 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3149 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2012 | 227 | 0.020 |
Why?
|
Survivors | 1 | 2021 | 2369 | 0.020 |
Why?
|
Camptothecin | 1 | 2014 | 591 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2631 | 0.020 |
Why?
|
Th1 Cells | 1 | 2015 | 1042 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 3048 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12159 | 0.020 |
Why?
|
Th2 Cells | 1 | 2015 | 1071 | 0.020 |
Why?
|
Immunosuppressive Agents | 2 | 2013 | 4190 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2015 | 10423 | 0.020 |
Why?
|
Adult | 5 | 2024 | 221120 | 0.020 |
Why?
|
Signal Transduction | 2 | 2024 | 23419 | 0.020 |
Why?
|
Tumor Escape | 1 | 2012 | 371 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41496 | 0.020 |
Why?
|
Apoptosis | 2 | 2014 | 9478 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7189 | 0.020 |
Why?
|
Aged | 4 | 2024 | 169292 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2014 | 3778 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2024 | 58952 | 0.020 |
Why?
|
Hepatocytes | 1 | 2014 | 1230 | 0.020 |
Why?
|
Proteomics | 1 | 2021 | 3840 | 0.020 |
Why?
|
Down-Regulation | 1 | 2014 | 2916 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9417 | 0.020 |
Why?
|
Models, Biological | 1 | 2021 | 9458 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2015 | 18222 | 0.010 |
Why?
|
Monocytes | 1 | 2013 | 2570 | 0.010 |
Why?
|
Phosphorylation | 1 | 2014 | 8300 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2024 | 64681 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 11855 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15841 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1885 | 0.010 |
Why?
|
Child | 2 | 2022 | 80154 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18384 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2014 | 3044 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2014 | 2293 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8663 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10756 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2813 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 2015 | 3753 | 0.010 |
Why?
|
Liver | 1 | 2014 | 7512 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2014 | 4310 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 22174 | 0.010 |
Why?
|
Mutation | 1 | 2020 | 30004 | 0.010 |
Why?
|
Young Adult | 1 | 2021 | 59222 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11733 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 88300 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13632 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 15521 | 0.000 |
Why?
|